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Abstract 
Collaboration can be challenging; nevertheless, the emerging successes of large, multi-
partner, multi-national cooperatives and research networks in the biomedical sector have 
sustained the appetite of academics and industry partners for developing and fostering 
new research consortia. This model has percolated down to national funding agencies 
across the globe, leading to funding for projects that aim to realise the true potential of 
genomic medicine in the 21st Century and to reap the rewards of ‘big data’. In this 
Perspectives article, the experiences of the RA-MAP consortium, a group of 300 individuals 
affiliated with 21 academic and industry organisations that are focused on making genomic 
medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner 
collaboration in the UK are highlighted and wide-ranging solutions are offered that might 
benefit large research consortia around the world.  
 
 
[H1] Introduction 
Over the past few years, the relative failure by scientists to reap the benefits of the 
genomics revolution, along with the pressing challenges and perceived opportunities that 
accompany the analysis of ‘big data’, have led to a concerted drive towards the 
development of cooperative academia–industry initiatives across a range of diseases1,2. 
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This move towards consortia acknowledges the need to advance healthcare initiatives in a 
systematic way and places emphasis on the collective harnessing of knowledge, resources 
and expertise in ways that are both complementary and mutually beneficial to all parties3-6. 
Central to these initiatives has been the creation of nonexclusive consortia in pre-
competitive areas of research (research aimed at the generation of new knowledge) that 
capitalise on expertise from multiple sources and reward all partners for their 
contributions7,8. In this Perspectives article, we describe the experience of setting up the 
RA-MAP consortium and highlight some of the challenges we faced and solutions we 
adopted to successfully direct a collaborative consortium focused on rheumatoid arthritis 
(RA).  
 
[H1] Stratified medicine  
Stratified medicine has been defined in a wide variety of ways9: the Association of the 
British Pharmaceutical Industry (ABPI) defines it as “the ability to classify individuals into 
subpopulations that differ in their susceptibility to a particular disease or their response to 
a particular treatment”10. The term has also been used interchangeably with precision, 
personalised or P4 medicine9,11. In line with these definitions, and in an effort to realise the 
full potential of stratified medicine12, funding bodies have sought to support research that 
provides new insights into disease mechanisms, enabling the tailoring of existing 
treatments to individuals and paving the way for the development of new treatments, 
diagnostic methods and care pathways13,14.  
 
Arguably, physicians have been practicing precision medicine for centuries, individualizing 
therapy on the basis of personalised clinical assessment in combination with rudimentary 
investigations such as haematological and biochemical profiles, as well as radiographic 
imaging and histopathological investigations. Contemporary concepts of tailoring therapy 
to specific patient subgroups have been driven by a growing appreciation of pathway 
biology, in which common clinical syndromes are underpinned by aberrations in specific 
molecular and cellular processes, and the development of sophisticated laboratory tools to 
define these distinct pathways15,16. Sequencing and annotation of the human genome, 
coupled with advances in next generation sequencing technology, have been at the 
forefront of stratified medicine, enabling researchers to uncover molecular associations 
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with specific disease phenotypes17,18, drug responses and drug toxicities19, as well as to 
define novel pathogenic molecular pathways that underpin disease risk20. Genomic 
fingerprinting, along with transcriptomics, epigenomics, proteomics and metabolomics, are 
just a few of the ‘omics’ technologies that enable a truly systematic and unbiased approach 
to understanding the molecular basis of disease. The omics revolution is generating data on 
an unprecedented scale21, leading to the need for major advances in informatics, data 
integration, data science and methods for analysing big data, a set of disciplines that are 
often captured under the umbrella term of ‘systems biology and bioinformatics’22. The 
overriding goal of stratified medicine is early, precise diagnosis of disease and early 
therapeutic intervention, applying “the five rights” of medication use: the right patient, the 
right drug, the right time, the right dose and the right route, a concept adapted from 
standards for safe medication practices23. A future goal of stratified medicine would be to 
use these data to define the pre-clinical disease state with a view to personalized 
preventative medicine. Such big data approaches are underpinned by the belief that the 
classical clinical phenotype of a disease such as RA is actually composed of a variety of 
distinct molecular endotypes24, each one predicated on inherited, environmental and 
stochastic differences between patients.  
 
Nowhere has stratified medicine had a greater effect to date than in cancer; genotyping 
patients for BRCA mutations25, screening patients for gene translocations26,27 and analysis 
of expression of ERBB2 combined with in situ tissue typing in patients with breast 
cancer28,29, for example, have transformed therapy through a deeper understanding of 
oncogenesis at the molecular level. This deeper knowledge of oncogenesis has led to 
cancer prevention and to the rational design of small molecule tyrosine kinase inhibitors 
and monoclonal antibodies, with proof-of-concept being established during clinical 
trials30,31. The stratification of patients according to their immune phenotype is also 
progressing rapidly in the field of checkpoint inhibitor therapy32-34. On the basis of these 
advances, there has been considerable interest in the past few years in applying these 
principles to other diseases that might benefit from a similar experimental approach. An 
academia–industry collaboration designed along the lines of the contemporary models 
outlined above would provide a strong platform from which to deliver such an ambitious 
programme of work.  
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[H1] MRC–ABPI-funded programmes  
In 2008, the UK Medical Research Council (MRC) published a strategic review of human 
immunology, which provided a roadmap for building capacity, for the creation of an 
interdisciplinary environment and for an increase in connectivity between institutions and 
sectors35. In 2009, in response to the last of these points, the MRC Human Immunology and 
Inflammation Initiative identified obstacles to closer academia–industry interaction: 
solutions to which included improved networking, improved access to human tissue 
samples and improved support for clinical researchers. Two disease-focused workshops, 
covering RA and chronic obstructive pulmonary disease, were held in 2010 to begin to 
address these important issues. The rationale for selecting RA as a model disease for this 
approach was driven by a combination of UK expertise in the field and specific unmet 
clinical needs and knowledge gaps for the disease. These unmet needs included robust 
strategies for the stratification of patients and suitable biomarkers to inform such 
stratification, technology to predict responses to specific therapies and molecular and 
cellular signatures to identify a state of true biological remission. At these workshops, the 
discussions focused on approaches to stratified medicine and placed particular emphasis 
on prioritising research into disease pathways and on how an ambitious and incisive 
programme of research might best be delivered. Key requirements for establishing a 
successful consortium were highlighted during these discussions and are summarised in 
Box 1. In 2011, the MRC–ABPI Inflammation and Immunity Initiative was formally launched 
in an attempt to address some of the specific unmet needs of patients with RA.  
 
[H3] The immunological concept. After considering these requirements (Box 1), the RA-
focused working group concluded that the missing element was a full understanding of the 
immune dysregulation that underpins RA. If the immunology of the disease could be better 
characterized, it followed that biomarkers could then be developed to stratify patients with 
the disease and to inform therapy choices. Theoretically, these cellular and molecular tools 
could be integrated into an immunological toolkit that would consist of a combination of 
clinical and laboratory parameters measured in patients with early RA that could be used 
to predict clinical responses to DMARDs, to monitor biological responses to therapy and to 
define a true state of biological remission. This proposal was predicated on the following 
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principles: the healthy immune system is associated with an immunological fingerprint that 
can be defined by serum, cellular and/or molecular signatures in peripheral blood; RA is 
associated with detectable perturbations of the immune system at very early stages of 
disease36 that can be used to distinguish subsets of patients; restoration of immune health 
in patients with RA might be inducible by therapies that target these perturbations; and 
that clinical remission is associated with a biological state that might have similarities to a 
healthy immune system. If successful, it was thought that such an approach could have an 
immediate effect on our understanding of a broad range of immune-mediated 
inflammatory diseases. 
 
[H3] The RA-MAP Consortium. In 2012, following a successful funding application focused 
on the principles described above, the Rheumatoid Arthritis MRC–ABPI (RA-MAP) 
Consortium was conceived. The consortium has since expanded to include 11 industry 
partners and 10 UK academic partners who share a deep-rooted enthusiasm for 
translational science in the field of immunology and inflammation in the pre-competitive 
space (Supp. Fig. S1). Membership of the consortium reflected contributions and 
commitments by various partners to genomic medicine, genetics and immunology and 
inflammation biology; expertise in immune phenotyping, metabolomics and proteomics; 
clinical expertise in assembling and curating patient cohorts and deep clinical phenotyping; 
and centres of excellence in experimental medicine with a focus on early inflammatory 
arthritis. Unusually, there was a close relationship between the funding body and the 
researchers, which created a new paradigm for collaborative working.  
 
The RA-MAP Consortium has similarities to other research networks that focus on research 
into rheumatic diseases (Table 1), including the Accelerating Medicines Partnership (AMP) 
RA and systemic lupus erythematosus network, a partnership that was launched in 2014. 
This US network seeks to define new therapies and diagnostic technologies for rheumatic 
autoimmune diseases by utilising a systems-level understanding of transcriptomic 
signatures derived from synovial, kidney and skin tissues. Along similar lines, the European 
Union (EU) funded PRECISESADS consortium focuses on redefining autoimmune diseases at 
a molecular level (Table 1). In operational terms, EU consortia have benefited considerably 
from the experiences of previous academia–industry partnerships, such as AutoCure, 
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MASTERSWITCH and Be the Cure (BTCure). The longevity of these programmes has served 
to fuel the productivity of research and to facilitate collaborations between public sector 
and private sector organisations. Since its inception, the MRC Stratified Medicine strategic 
initiative has also supported several other consortia that focus on immune-mediated 
inflammatory diseases (Table 1).  
 
A key challenge for the RA-MAP Consortium was to harness the synergistic skillsets of 
pharmaceutical companies, biotechnology companies and academic partners to develop a 
programme of activities that would address each specific scientific goal. To do so would 
require a sizeable new inception cohort of treatment-naive patients with RA who had a 
relatively short duration of symptoms and would be willing to provide biological samples. 
This cohort of patients was called Towards a Cure for Early RA (TACERA), and the samples 
from these patients provided the substrate for cutting-edge analytical techniques. The next 
step was to apply innovative systems approaches to analyse and assemble the data from 
multiple omics platforms into predictive algorithms, with the ultimate aim being the 
development of a set of informative assays that would provide a toolkit to facilitate patient 
stratification in a clinical setting (Fig. 1). A cohort of healthy individuals who were followed 
longitudinally following vaccination with a neoantigen was enrolled to provide a suitable 
control population with which to compare the signatures of immune dysregulation 
identified in patients with RA.  
 
Although each industry partner had their own strategic reasons for joining the consortium, 
the overriding motivation of these companies to partner with academia was the shared 
recognition that this study would generate data in a real-world population of patients with 
RA that could improve our understanding of the subsets of disease and associated 
immunological phenotypes that characterize the early phase of RA. Working collaboratively 
with companies and various academic centres was thought to increase the chances of 
producing clinically relevant knowledge about opportunities for intervention and indicators 
of response in these patients. To achieve these goals, the RA-MAP Consortium divided its 
tasks into various work packages (see Supp. Fig. S2).  
 
 	 7 
For the remainder of this Perspectives article we aim to describe some of the operational 
and scientific challenges that are faced by large research consortia and to highlight 
solutions that can be adopted to overcome such challenges. 
 
[H1] Challenges and solutions 
Some of the key challenges that are faced by academia–industry consortia are summarised 
in Box 2; further insights and suggested solutions derived from the experience of the RA-
MAP Consortium are described in detail below.  
 
[H3] The contract. A major challenge for any consortium is one of scale. In any group of 
academic and industry partners who each have distinct agendas, experiences and 
governance structures, individual partners will have different expectations. This 
discrepancy requires sympathetic management so that the ambitions of all parties can be 
met. Agreement of the scientific goals of the consortium provides a common purpose, for 
which each partner can identify their potential contributions and resource provision. 
Tangible benefits for industry partners are central to success and to the sustainable 
engagement of such partners; each company will value research ‘currency’ in a different 
way, but good examples might include access to deeply phenotyped cohorts of patients, 
access to downstream data and sharing of samples among partners. Interactions between 
and operations involving multiple institutions require a set of clear ground rules that go 
beyond a ‘terms of reference’ template. One possible solution is the consortium 
agreement, which provides an operating framework that emphasizes the obligations and 
responsibilities of leadership and membership and contains guidelines about the transfer 
and use of materials, liabilities and indemnity of each party, details of project management 
and data management practices including data protection and, importantly, publicity, 
publication and intellectual property rights. In essence, the agreement needs to be simple, 
pragmatic and a point of reference for the lifetime of the consortium and beyond. 
 
[H3] Who owns the data? Reaching agreement over data protection and ownership can be 
a major challenge for research consortia because priorities and expectations can vary 
between the private and public sectors, notwithstanding the nuances that research in the 
pre-competitive space can offer. Nonetheless, this is an area in which the experience of 
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industry can add value to a consortium; helping to define relevant background to the 
project, supporting registration and protection of intellectual property rights arising from 
the data, filing and prosecuting patent applications or assisting in actions relating to 
infringement of intellectual property rights. In return, academic partners might agree to 
grant worldwide non-exclusive licenses to any industry partner to use the results of 
experiments and intellectual property for commercial purposes, taking into account the 
relative contribution made to the consortium by that industry partner. Members of the RA-
MAP Consortium learned that much time can be saved, and barriers promptly overcome, 
by facilitating frequent, robustly managed communication between the intellectual 
property and technology transfer offices of each partner from the very outset.  
 
[H3] How can industry partners contribute? Resource frameworks differ greatly depending 
on the scale and context of the research programme and the funding agency involved. For 
example, industry partners might be required to pledge specific levels of support, such as 
in-kind contributions, contributions of skilled personnel, funding for specific research 
projects or provision of access to technology platforms. Such has been the approach of the 
EU Framework 7 and Horizon 2020 programmes with respect to matched contributions 
from European Federation of Pharmaceutical Industries and Associations (EFPIA) 
partners37. Commitment to provide matched-funding from the outset has obvious 
advantages; but although these ground rules might not apply to all consortia, there are 
imaginative ways that industry partners can support the research agenda. The RA-MAP 
Consortium benefited greatly from the patient level data, advice on the setup of and study 
operations for the TACERA study, omics platforms, advice on the management of 
informatics and bioinformatics and statistical analysis that were provided by industry 
partners.  
 
[H3] Consortium operations. Concepts of project management differ widely across sectors, 
yet robust management can determine the success or failure of a project. So, what are the 
options? Experience suggests that oversight of multi-partner projects can be greatly 
facilitated by a small executive Consortium Management Board that is co-chaired by 
industry and academia principal investigators. This board might take responsibility for 
coordinating activities and for reporting progress to the funder. A larger Project Steering 
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Group, comprising representatives of all consortium partners, can operate as the decision-
making body, using a legally binding consortium agreement as its terms of reference. 
Investment in full-time project managers with experience in both academia and industry 
can reap dividends. As the ‘operators of operations’, project managers are essential for 
organising meetings and maintaining a sharp focus on project timelines, deliverables and 
milestones, as well as for the robust management of high risk work packages, and are 
increasingly appreciated as vital assets in the academic setting. Infusing a project with a 
momentum that will last for its lifetime can be critical to success — an exemplar operating 
structure is illustrated in Supp. Fig. S3.  
 
[H3] Coordinating biological sampling at multiple sites. Traditionally, the acquisition of an 
extended portfolio of samples, including intensive sampling over short periods of time, has 
been the remit of small, single-centre experimental medicine studies. Accredited centres 
specializing in phase I clinical trials and contract research organisations have streamlined 
this process over several decades, facilitated by the proximity of patients to the lab, short 
times from venesection to processing of samples and tried and tested standard operating 
procedures (SOPs) for processing, storing and analysing fresh samples. Large, multi-centre 
studies present a challenge in this regard, necessitating sizeable efforts to harmonise the 
acquisition, processing and storage of prospectively acquired biological samples, and 
compromises in terms of sample range and assay complexity. Sampling is often limited in 
such multi-centre studies to the monitoring of drug safety using local accredited clinical 
laboratories.  
 
To address the challenge of collecting samples at multiple sites, the RA-MAP Consortium 
established a hub and spoke network of seven academic laboratory hubs across England 
and Scotland serving 28 recruiting centres. This approach enabled the transportation of 
study samples from any patient recruiting site to a lab within 4 hours of venesection. The 
requirements for sample transport, and for subsequent processing and storage, were 
clearly documented in study SOPs and protocols, with each step of the sample transport 
process carefully logged by study staff. Specifically designed sample tracking and logging 
software was placed in each of the hub laboratories along with the necessary hardware, 
including barcode scanners. SOPs for complex sample processing were developed by the 
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relevant partners, scrutinised by industry partners, and refined prior to participant 
recruitment. This approach enabled high quality, barcoded aliquots of serum, peripheral 
blood cells, whole blood RNA, RNA from lymphocyte and monocyte subsets purified in each 
laboratory, genomic DNA and urine to be processed and stored (Supp. Fig. S4). Combined 
input from academic and industry partners can ensure that sampling protocols are 
optimised to support immune phenotyping, as well as metabolomic, proteomic and 
transcriptomic analyses. In addition, sample procurement of this magnitude requires 
sample storage that facilitates long-term access to samples by the wider research 
community. Well-funded national repositories are ideally suited to provide this platform; in 
the UK, the UK Biobank provides such a resource.  
 
[H3] Quality control. By centralising sample analysis, single-centre studies can ensure the 
consistency and quality of sample processing and analysis on fresh material. However, 
when a broad portfolio of analytical platforms, analysis and expertise are required, there 
are several pragmatic approaches that can be adopted. Analysing all samples at a single 
sitting has obvious advantages, especially for transcriptomics, proteomics and 
metabolomics; when performing such assays at scale (for example, RNA extraction and 
microarray analysis), outsourcing can prove to be both cost effective and scientifically 
justifiable. A particular challenge for multi-centre studies is flow cytometric analysis, 
because cell staining protocols vary widely and hardware and machine settings can 
dramatically alter immune phenotypes, not to mention the varying expression profiles 
generted by different antibodies and fluorophores. To address this challenge, aliquots of 
cryopreserved peripheral blood cells can be distributed to designated laboratories that 
have expertise in the deep phenotyping of a single leukocyte subset. Flow cytometer 
configurations can be harmonised and batches of fluorescence-conjugated monoclonal 
antibodies can be purchased in bulk and distributed to each centre to minimise 
experimental variability across sites and between assays. In cases when samples are 
evaluated by flow cytometry at multiple time-points, additional measures can be adopted 
to minimise batch effects (for example, by applying corrections using standard tools such 
as COMBAT38).  
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[H3] Curating the data. Data are one of the defining metrics for determining the success of 
a consortium. Study participant data is often derived from multiple sources, especially 
when combining clinical, laboratory, imaging and omics datasets. As an example, the RA-
MAP Consortium oversaw the recruitment of an inception cohort of patients with RA 
(participants in the TACERA study), who they followed from first presentation for up to 18 
months, accumulating over 1,280 baseline and follow-up visits from 275 study participants. 
The scale of the programme and the breadth and depth of data acquired necessitated 
investment in data cleaning, curating and storage, in accordance with data protection 
guidelines and sharing and communication policies, which needed to comply with 
requirements for patient confidentiality on the one hand while facilitating data analysis on 
the other. For the TACERA study, data were securely transferred and pseudo-anonymised 
using the OpenPseudonymiser package before undergoing a curation process, which 
included data integrity checks and semantic normalisation. The curated and reformatted 
data were uploaded to TranSMART, a data warehouse that enables data access, 
visualisation, exploration and download to all members of the consortium (Supp. Fig. S5). 
The local platform of TranSMART belonging to the RA-MAP Consortium has provided 
service to 82 users from multiple organisations and stores 37GB of data on the MRC 
eMedLab cloud computing facility, offering high performance computing capacity, a 
solution for long-term data sustainability and an appropriate environment for future meta-
analyses by the rheumatology and immune-mediated inflammatory disease research 
communities.  
 
[H3] Analysis of multi-omic data. When dealing with large volumes of data, challenges arise 
beyond storage. The RA-MAP Consortium’s portfolio of studies generated approximately 
40 million analysis-ready data points from approximately 1 billion raw data points derived 
from more than 5,721 patient samples. The results of each omics platform investigation 
were stored in the TranSMART data warehouse, which provided an integrated view of 
omics platforms and linked clinical phenotypes, alongside a highly curated selection of pre-
existing public data. TranSMART was chosen as it provided the RA-MAP Consortium and 
their partners with a unified, secure and, critically, sustainable research environment that 
offered on-board analytical capacity (including additional plugins such as SmartR39), data 
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export and an R application programming interface, which enabled the use of a broad 
range of systems biology and machine learning methods for biomarker discovery.  
 
Encouraging a sense of ownership of the data among all members of a consortium and 
overseeing the analysis by multiple parties require robust management. Agreement 
between partners and a clear alignment of goals between clinicians and the analytical 
teams, which might comprise biostatisticians, bioinformaticians and systems biologists 
from multiple partners, are essential for sustaining research momentum, maximising 
output and for maintaining focus on pre-defined clinical questions. The RA-MAP 
Consortium found the adoption of a series of ‘lab meeting’-style teleconferences to be 
particularly productive. During these meetings, bioinformaticians could discuss the analysis 
of data on individual platforms and systems biologists could direct overall data integration 
while at the same time retaining a sharp focus on immunologically relevant research 
questions.  
 
[H3] Publication policy. Communicating the outcome of large scale consortia-driven 
projects is extremely important. The research community is familiar with manuscripts that 
are co-authored by large numbers of investigators; however, authorship requires further 
consideration when multiple parties have contributed equally. Discussions with publishers 
indicate that assigning authorship collectively to a consortium is acceptable; although for 
operational and pragmatic reasons, either one or a few lead investigators can be 
designated as named and/or corresponding authors. To appropriately acknowledge the 
contributions of the consortium members in general, and the work of specific investigators 
in particular (such as graduate students, postdoctoral researchers, statisticians and 
bioinformaticians), separate documents listing specific contributions can be submitted to 
the relevant journal as supplementary information in accordance with journal policy. In 
addition, this approach provides a process whereby credentials for a larger number of 
academic investigators can be evaluated as part of the UK government’s Research 
Excellence Framework, a process whereby higher education institutions are allocated 
resources on the basis of research excellence. It is prudent for publication policies such as 
these to be defined from the outset of collaborative projects and included in the 
consortium agreement.  
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[H3] Meeting the milestones. Strategies for monitoring progress and outputs from large 
collaborative groups can vary from a remote approach (for example, annual written 
reports), which is typical of large EU consortia, to a more intense and actively managed 
relationship between funder and researcher. The latter option is the chosen method for 
the stratified medicine consortia funded by the MRC, who opted for a formal and engaging 
face-to-face method of review. Members of the Consortium Management Board were 
requested to attend face-to-face reviews of milestones and deliverables by an independent 
panel of experts convened by the MRC on a 6-monthly basis. Progress was robustly and 
critically reviewed and additional targets established or revised when required and, on 
occasion, suggestions for additional analyses were given. Although challenging and highly 
supportive, this review process was uncompromising in its expectations of milestone 
delivery. During each review session, the panel of experts sought to challenge the science 
and experimental approach of the consortium, seeking solutions at every opportunity and 
strategies to mitigate risk. The funding body also gained from these review sessions 
through a deeper understanding of the steps required to develop operational and 
functional research consortia.  
 
[H1] Future directions 
Using the TACERA early RA cohort, the RA-MAP Consortium set out to stratify patients with 
RA on the basis of clinical findings (patients mapping to distinct trajectories), whole blood 
transcriptomic profiles (uncovering major disease endotypes) and clusters of serum 
analytes that might guide treatment choices at the time of disease onset. At the time of 
writing, data from the TACERA study that fulfil these aims have been submitted for 
publication. In the near future, the RA-MAP Consortium aims to focus on integration of 
these stratification tools into clinical practice. The multi-omics approach of the RA-MAP 
Consortium strongly indicates that disease stratification might be multi-dimensional and 
require stratification of patients by use of an immunological toolkit, depending on the 
specific clinical question being asked. Once validated, the priority will be to apply the 
discovered stratification algorithms in a clinical trial setting.  
 
[H1] Conclusions  
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The RA-MAP Consortium, comprising more than 300 investigators, has embarked on a 
stimulating journey, negotiating its way through difficulties at various points along the way. 
The successful operation of a large consortium of academic and industry investigators 
relies on several key factors: the development of a functional multi-partner research 
infrastructure; a strong pre-competitive collaborative ethos; an uncompromising emphasis 
on the generation of high-quality data; the nurturing of relationships for a productive 
research community; the sharing of insights about understanding the disease and its 
treatment; and the sharing of outputs through delivery of a publication plan that targets 
high-impact journals. Under the existing framework of regulatory approvals, the RA-MAP 
Consortium is pleased to offer the wider research community access to data and samples 
as soon as our own investigations have been completed. We anticipate that this might be 
as early as February 2018 for samples, and the following year for access to data. This 
process will be actively managed by a dedicated Data and Sample Access Committee in a 
transparent manner, facilitated by a structured application form. 
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Box 1: Establishing a successful stratified medicine consortium. 
Several key elements are required when setting up an academia–industry partnership:  
• A consensus on the importance of identifying common disease pathways. 
• Engaged industrial partners with emerging drug pipelines. 
• Existing efficacious therapies that might be suitable for repurposing. 
• An urgent need for disease phenotyping and biomarker-based patient stratification. 
• The need for a better understanding of the relationship between clinical and 
pathological phenotypes.  
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• The availability of emerging technologies to redefine disease subtypes at a molecular 
and cellular level. 
• Regional or national co-localisation of partners. 
• A rich patient bioresource. 
• Access to clinical research infrastructures, for example the National Health Service 
and National Institute for Health Research in the UK. 
• Enthusiastic support from patient groups. 
 
Box 2: Challenges faced by research consortia. 
[b1] Agreement as to the terms of reference and ground rules for consortium operations 
Generate a contract or consortium agreement with input from the contract and legal 
teams of all partners from the outset. 
[b1] Data ownership 
In any pre-competitive project data can be shared and intellectual property 
arrangements can be addressed directly in the consortium agreement. 
[b1] Industry contributions 
Contributions from industry partners should be agreed from the start of the project. 
Examples of contributions should be provided that cover the areas of specific interest or 
expertise of each partner. 
[b1] Project management 
Management structures are essential and part of ‘normal business’ for industry partners. 
Capitalise on private sector expertise to establish lean, functional committees with clear 
terms of reference. Invest in a project manager, ideally with both academic and industry 
experience. 
[b1] Managing staff turnover 
Anticipate and redistribute resources to support the training of incoming technical and 
research staff; close liaison with industry partners to identify new colleagues with 
relevant skills and experience is essential.  
[b1] Building a strong collaborative ethos 
Identify areas of expertise and establish working groups made up of individuals from 
across all sectors who share common goals and will commit to regular teleconference 
meetings. 
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[b1] Recruiting site approval and set-up 
Engage contract research organizations to support activities such as coordinating the 
acquisition of documentation for timely site-specific regulatory approval. 
[b1] Quality control 
Quality control applies as much to study protocols and standard operating procedures, as 
it does to sample acquisition, processing and storage and to data analysis; procurement 
should be robust and outward-looking if the necessary expertise does not exist within 
the consortium 
[b1] Data analysis 
Invest in state-of-the-art data warehouse capabilities and facilitate access by all parties. 
Define research priorities and construct a mutually agreed Data Analysis Plan. Frequent 
opportunities for all partners to discuss results are essential to maintain momentum. 
[b1] Publication 
Agree to a publication policy and plan that provides shared authorship, where 
appropriate, and recognizes the contributions of the extended network of investigators. 
[b1] Scientific review of milestones 
Project reviews should be agreed with the funding organisation, as appropriate; but 
should be regular, robust and led by an independent expert advisory committee and 
chair. 
 
Figure 1: Stratification of patients with rheumatoid arthritis.  
Stratification of patients with rheumatoid arthritis (RA) can occur at several points during 
the natural history of the disease. Multiple platforms can be adopted to stratify patients 
throughout the disease course; including serotyping, clinical and immunological 
phenotyping, genotyping and imaging.  
 
Table 1: Academia–industry consortia in immune-mediated rheumatic diseases 
Consortium Contributors Website 
(1) International consortia 
AMP RA and SLE 
network 
NIH 
US FDA 
Ten industry partners  
https://amp-ralupus.stanford.edu/ 
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Multiple academic 
research units 
PRECISESADS 
consortium 
Five EFPIA partners 
Two SMEs 
21 academic partners 
http://www.imi.europa.eu/content/precisesads 
AutoCure Six EFPIA partners 
20 academic partners 
http://www.crb.uu.se/research/projects/autocure/ 
MASTERSWITCH Four SMEs 
15 academic partners 
http://cordis.europa.eu/result/rcn/147588_en.html 
Be the Cure Nine EFPIA partners 
Six SMEs 
24 academic partners 
http://btcure.eu 
Rheuma 
Tolerance for 
Cure 
Six EFPIA partners 
Two SMEs 
12 academic partners 
http://cordis.europa.eu/project/rcn/211964_en.html  
MRC Stratified Medicine consortia 
The MATURA 
consortium  
Ten industry partners 
12 academic partners 
Joint funded with ARUK 
http://www.matura.whri.qmul.ac.uk 
The PSORT 
consortium 
Seven industry partners  
12 academic and NHS 
partners 
http://www.psort.org.uk 
The 
MASTERPLANS 
project 
Four industry partners 
Eight academic and NHS 
partners 
http://www.lupusmasterplans.org/home.html 
 
AMP, Accelerating Medicines Partnership; ARUK, Arthritis Research UK; EFPIA, European 
Federation of Pharmaceutical Industries and Associations; FDA, Food and Drug 
Administration; NIH, National Institutes of Health; NHS, National Health Service; RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; SME, small or medium sized 
enterprise. 
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Subject ontology terms 
Health sciences / Rheumatology / Rheumatic diseases / Rheumatoid arthritis 
[URI /692/4023/1670/498] 
Health sciences / Medical research / Preclinical research 
[URI /692/308/2778] 
Health sciences / Medical research / Translational research 
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Supplementary Figure S1 – The RA-MAP Consortium. Participating academic (beige) and industry (green) partners are 
represented (centre), with work package lead partners identified in red. Collaborators and Participating NHS sites are also listed 
(left and right, respectively).
Eisai
Abbvie
SomaLogic
Simomics
Predictors of 
Remission
Models of Clinical 
Remission and 
Response in RA 
Patients (3555)
Pooled Data from the 
Control Arm of RCTs
PREVeNTRA
Register of FDRs of RA 
to evaluate predictors 
of the development of 
RA (1846)
Clinical
Lifestyle & 
demographic
Lifestyle & 
demographic
Genetics & 
serology
RA Risk Factor Profile
Prediction Algorithms
Vaccine sub study
Immune response in healthy 
subjects receiving vaccination
(49)
TACERA
Longitudinal 
observational study of 
patients with early RA
(275)
Clinical 
phenotyping & 
Imaging
Extended 
serotyping & 
proteomics
Flow 
cytometry
Genetics
Metabolomic
s
Transcriptomics
The Immune Toolkit
A standard assay package to measure immune status of patients
Complex Immune Phenotyping
Supplementary Figure S2 – The RA-MAP Research Programme. The RA-MAP Research Programme. The breakdown of 
research tasks is illustrated according to experimental goals, which focused on (A) RA risk profiling through the development of
prediction algorithms and (B) the development of an immune toolkit for patient stratification.
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Supplementary Figure S3: Project management and reporting lines. The operational structure for coordinating activities of the
RA-MAP Consortium by research work package. ABPI, Association of the British Pharmaceutical Industry; I&I, Immunity and 
Inflammation; LOS, longitundinal observational study; MRC, Medical Research Council; PM, project manager; PoC, proof-of-
concept; WP, work package.
Supplementary Figure S4: RA-MAP core technologies. For the TACERA study, biological samples were acquired at every 3-
monthly study visit and shipped to academic laboratory hubs for processing and storage. Subsequently, samples were 
distributed to specialist units for analysis using the platforms shown.
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Supplementary Figure S5: Managing ‘big data’. Schematic highlighting the structure and constituents of the data from the RA-
MAP Consortium and affiliated datasets.
